cilostazol has been researched along with roflumilast in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YY; Li, Z; Luo, HB; Wu, D; Wu, Y | 1 |
| Bai, L; Gong, J; Jin, Y; Peng, T; Shi, J; Tong, R; Wei, X; Zhou, Y | 1 |
| Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M | 1 |
3 review(s) available for cilostazol and roflumilast
| Article | Year |
|---|---|
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors | 2018 |
Inhibitors of phosphodiesterase as cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2018 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2022 |